ClinicalTrials.gg
CompletedNCT00428974Updated Feb 8, 2023Results posted

Safety and Efficacy Study of CF101 to Treat Psoriasis

A Phase 2 interventional study of CF101 1mg and CF101 2mg in Plaque Psoriasis, sponsored by Can-Fite BioPharma. Completed at 4 sites in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Psoriasis with a site in Israel — none open to participants now, 3 under way, 1 of them phase 3. Psoriasis · Israel.

Enrollment
29th of 37
76 · median 293
Started
2007
with 1 other
Phase 2
8 of 44
none open now
Registered
2nd of 44
by date
Lead sponsor
3 of 44
Can-Fite BioPharma

Among the 44 studies in Psoriasis with a site in Israel, this one is the 29th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2007, is one of 8 in phase 2, and was the 2nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 44 studies in Psoriasis with a site in Israel is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies in Psoriasis with a site in Israel as a file.
02

Study summary

This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of treatment will be carefully assessed through clinical and laboratory monitoring. The effect of treatment on psoriasis will be evaluated through standard techniques of examination and measurement of the severity of skin involvement.

Read the detailed description

This is a Phase 2, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study in adult males and females, ages 18 to 70 years, inclusive, with a diagnosis of moderate-to-severe chronic plaque psoriasis. At the Screening Visit, patients who provide written informed consent will have screening procedures performed, including a complete medical history, medication history, physical examination, including height, weight, blood pressure, pulse rate and temperature, and clinical laboratory tests.

Eligible patients will be those who have not received systemic retinoids, corticosteroids, or immunosuppressants (e.g., methotrexate, cyclosporine) within 6 weeks prior to initiation of study; or high potency topical corticosteroids (Class I-III), keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles); and UV or Dead Sea therapy within 4 weeks prior to initiation of study treatment. Eligible patients will be sequentially assigned to 1 of 3 dosing cohorts:

Cohort 1: CF101 1 mg (15 patients) or Placebo (5 patients); Cohort 2: CF101 2 mg (15 patients) or Placebo (5 patients); Cohort 3: CF101 4 mg (15 patients) or Placebo (5 patients).

Medication will be taken orally q12h for 12 weeks. Disease activity will be assessed using the Psoriasis Area and Severity Index (PASI) and the Physician Global Assessment (PGA). Patients will return for assessments at Weeks 2, 4, 8, 12 and 14.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 70 years of age, inclusive;
  • Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%, as judged by the Investigator;
  • Duration of psoriasis of at least 6 months;
  • PASI score ≥10;
  • Body weight ≤100 kg;
  • Candidate for systemic treatment or phototherapy for psoriasis;
  • is normal or shows abnormalities which, in the judgment of the Investigator, are not ;
  • Females of must have a negative serum pregnancy test at screening;
  • Females of child-bearing potential must be willing to use 2 methods of deemed adequate by the Investigator (for example oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;
  • Ability to complete the study in compliance with the protocol; and
  • Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  • Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis;
  • Treatment with systemic retinoids, , or (e.g., methotrexate, cyclosporine) within 6 weeks of the Baseline visit;
  • Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;
  • Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;
  • Treatment with a biological agent (including etanercept, adalimumab, efalizumab, infliximab, or alefacept) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;
  • History of poor clinical response to methotrexate after an adequate regimen and duration of treatment;
  • Treatment with systemic nonsteroidal anti-inflammatory drugs, beta-blockers, lithium, hydroxychloroquine, chloroquine, or systemic terbinafine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period;
  • Presence or history of uncontrolled asthma;
  • Presence or history of uncontrolled arterial hypertension or symptomatic hypotension;
  • Significant cardiac arrhythmia or conduction block, congestive heart failure ( Class 3-4), or any other evidence of heart disease or clinically significant findings on screening ;
  • level \<9.0 gm/L;
  • count \<125,000/mm\^3;
  • White blood cell count \<3500/mm\^3;
  • Serum creatinine level greater than 1.5 times the laboratory's ;
  • Liver aminotransferase levels greater than 2 times the laboratory's upper limit of normal;
  • Pregnancy, planned pregnancy, lactation, or inadequate as judged by the Investigator;
  • History of within the past 5 years (excluding basal cell carcinoma of the skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely excised);
  • Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study;
  • Participation in another drug or vaccine trial concurrently or within 30 days; or within 5 half lives of a biological investigational product, whichever is longer;
  • Other conditions which would confound the study evaluations or endanger the safety of the patient.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    CF101 1 mg

    Drug: CF101 1mg

  • Experimental
    CF101 2mg

    Drug: CF101 2mg

  • Experimental
    CF101 4mg

    Drug: CF101 4mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • CF101 1 mg q12 hours for 12 weeks

    Also known as: IB-MECA

  • CF101 2 mg q12 hours for 12 weeks

    Also known as: IB-MECA

  • CF101 4 mg q12 hours for 12 weeks

    Also known as: IB-MECA

  • DrugPlacebo

    Placebo tablets q12 hours for 12 weeks

    Also known as: Inactive pill

06

What researchers measure

Primary outcomes

  1. Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score

    PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement

    Time frame: 12 weeks minus baseline

Secondary outcomes

  1. The Number of Patients Who Achieve a Score of "Almost Clear" or "Clear" by Physician's Global Assessment (PGA)

    PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome

    Time frame: 12 weeks

07

Results

Posted Sep 26, 2011

Participant flow

Participant flow — Overall Study
MilestoneCF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlacebo
Started25171519
Completed17171416
Not completed8013

Outcome measures

PrimaryChange From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score

PASI scale is sum of redness, thickness, and scale scores, ranging from 0 (no disease) to 72 (most severe possible score); lower scores, i..e., negative change from baseline, indicate improvement

Time frame:
12 weeks minus baseline
Reported as:
Mean · Scores on a scale
Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score
Scores on a scaleCF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlacebo
Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score-0.67 ± 8.9-8.8 ± 7.0-4.1 ± 7.8-2.7 ± 9.4
Statistical analysis
  • CF101 2 mg BID vs Placebo · t-test, 1 sided · p = 0.031
SecondaryThe Number of Patients Who Achieve a Score of "Almost Clear" or "Clear" by Physician's Global Assessment (PGA)

PGA is a scale from 0 (clear, no disease) to 5 (most severe score); patients who improve to 0 (clear) or 1 (minimal disease) are tabulated in this outcome

Time frame:
12 weeks
Reported as:
Number · Number of treated patients
The Number of Patients Who Achieve a Score of "Almost Clear" or "Clear" by Physician's Global Assessment (PGA)
Number of treated patientsCF101 1 mg BIDCF101 2 mg BIDCF101 4 mg BIDPlacebo
The Number of Patients Who Achieve a Score of "Almost Clear" or "Clear" by Physician's Global Assessment (PGA)0412
Statistical analysis
  • CF101 2 mg BID vs Placebo · Fisher Exact · p = <0.05

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 1 mg Twice Daily (BID)—0/24 (0%)2/24 (8.3%)
CF101 2 mg BID—0/17 (0%)1/17 (5.9%)
CF101 4 mg BID—0/15 (0%)1/15 (6.7%)
Placebo—1/19 (5.3%)1/19 (5.3%)
Most frequent serious events
Most frequent serious events
EventCF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlacebo
Atrial fibrillationCardiac disorders0/240/170/151/19
Most frequent other events
Most frequent other events
EventCF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlacebo
ArthropathyMusculoskeletal and connective tissue disorders2/240/170/150/19
SinusitisRespiratory, thoracic and mediastinal disorders0/240/171/150/19
Urine oxalateRenal and urinary disorders0/240/171/150/19
Uterine bleedingReproductive system and breast disorders0/240/171/150/19
Otitis externaEar and labyrinth disorders0/241/170/150/19
Back painMusculoskeletal and connective tissue disorders0/240/170/151/19
ChillsGeneral disorders0/240/170/151/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlaceboTotal
<=18 years00000
Between 18 and 65 years1916141766
>=65 years51129
Age, Continuous
Age, Continuous(years)CF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlaceboTotal
Mean51.5 ± 12.048.4 ± 10.245.3 ± 12.151.2 ± 10.449.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)CF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlaceboTotal
Female525517
Male1915101458
Region of Enrollment
Region of Enrollment(participants)CF101 1 mg Twice Daily (BID)CF101 2 mg BIDCF101 4 mg BIDPlaceboTotal
Israel2417151975
08

Study locations

4 sites
  • Haemek Medical Center
    Afula, Israel
  • Wolfson Medical Center
    Holon, Israel
  • Rabin Medical Center
    Petach Tikva, Israel
  • Sheba Medical Center
    Tel-Hashomer, Israel
09

References and documents

Publications

  • David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7. doi: 10.1111/j.1468-3083.2011.04078.x. Epub 2011 Apr 20. PubMed 21504485 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2007
First posted
Jan 30, 2007
Start
Jun 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Sep 26, 2011
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00428974
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Jan 30, 2007
Start date
Jun 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Sep 26, 2011
Last update
Feb 8, 2023

Study contacts

Michael David, MD
principal investigator · Rabin Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion